Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model

[1]  G. Casadesus,et al.  The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia , 2019, Front. Aging Neurosci..

[2]  M. Lewitt,et al.  The Role of Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins in the Nervous System , 2019, Biochemistry insights.

[3]  F. Tovar-Moll,et al.  Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models , 2018, Nature Medicine.

[4]  J. Zegarra-Valdivia,et al.  Serum Insulin-Like Growth Factor I Deficiency Associates to Alzheimer's Disease Co-Morbidities. , 2019, Journal of Alzheimer's disease : JAD.

[5]  A. Tumminia,et al.  Type 2 Diabetes Mellitus and Alzheimer’s Disease: Role of Insulin Signalling and Therapeutic Implications , 2018, International journal of molecular sciences.

[6]  N. Barzilai,et al.  40 YEARS of IGF1 IGF1: the Jekyll and Hyde of the aging brain , 2018 .

[7]  D. Munoz,et al.  The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non‐human primate model of Alzheimer's disease , 2018, The Journal of pathology.

[8]  A. Galina,et al.  Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-β oligomers , 2017, The Journal of Biological Chemistry.

[9]  W. Klein,et al.  Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers , 2017, Molecular biology of the cell.

[10]  M. Holzenberger,et al.  The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons , 2017, Brain : a journal of neurology.

[11]  Bryan J. Neth,et al.  Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial , 2017, Journal of Alzheimer's disease : JAD.

[12]  F. Gomes,et al.  Interaction of amyloid-β (Aβ) oligomers with neurexin 2α and neuroligin 1 mediates synapse damage and memory loss in mice , 2017, The Journal of Biological Chemistry.

[13]  L. Grinberg,et al.  Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study , 2017, PLoS medicine.

[14]  D. Tropea,et al.  Insulin-Like Growth Factor 1: At the Crossroads of Brain Development and Aging , 2017, Front. Cell. Neurosci..

[15]  S Lovestone,et al.  Insulin signalling in Alzheimer′s disease and diabetes: from epidemiology to molecular links , 2016, Journal of internal medicine.

[16]  T. Outeiro,et al.  Insulin‐like growth factor‐I gene therapy increases hippocampal neurogenesis, astrocyte branching and improves spatial memory in female aging rats , 2016, The European journal of neuroscience.

[17]  Wenhua Zheng,et al.  Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Disease , 2016, PloS one.

[18]  G. Taglialatela,et al.  The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice , 2016, Neurobiology of Aging.

[19]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[20]  O. Hanon,et al.  Low Serum Insulin-Like Growth Factor-I Predicts Cognitive Decline in Alzheimer's Disease. , 2016, Journal of Alzheimer's disease : JAD.

[21]  M. Holzenberger,et al.  Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance , 2015, The Journal of Neuroscience.

[22]  W. Sonntag,et al.  Growth hormone, insulin-like growth factor-1 and the aging brain , 2015, Experimental Gerontology.

[23]  S. Ferreira,et al.  Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease , 2015, Front. Cell. Neurosci..

[24]  W. Klein,et al.  Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis , 2015, Acta Neuropathologica.

[25]  学 赤沢,et al.  Glucose Tolerance Status and Risk of Dementia in the Community: The Hisayama Study , 2015 .

[26]  Emily H. Trittschuh,et al.  Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. , 2015, Journal of Alzheimer's disease : JAD.

[27]  S. Ferreira,et al.  Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease , 2014, Diabetes.

[28]  C. DeCarli,et al.  Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy , 2014, Neurology.

[29]  M. Stek,et al.  Insulin-like growth factor–1 and risk of late-onset Alzheimer's disease: findings from a family study , 2014, Neurobiology of Aging.

[30]  M. Schubert,et al.  The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. , 2014, CNS & neurological disorders drug targets.

[31]  S. Ferreira,et al.  How does brain insulin resistance develop in Alzheimer's disease? , 2014, Alzheimer's & Dementia.

[32]  Tzeng-Ji Chen,et al.  Diabetes Mellitus and the Risk of Alzheimer’s Disease: A Nationwide Population-Based Study , 2014, PloS one.

[33]  D. Munoz,et al.  TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. , 2013, Cell metabolism.

[34]  F. D. Felice.  Connecting type 2 diabetes to Alzheimer's disease. , 2013 .

[35]  C. Cavada,et al.  Loss of serum IGF-I input to the brain as an early biomarker of disease onset in Alzheimer mice , 2013, Translational Psychiatry.

[36]  W. Klein,et al.  Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight Aβ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers , 2013, The Journal of Neuroscience.

[37]  D. Foguel,et al.  Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice , 2012, Molecular Psychiatry.

[38]  Suzanne Craft,et al.  Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[39]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[40]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[41]  F. Metzger,et al.  Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency , 2012, Neuroscience Letters.

[42]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[43]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[44]  Mark A. Smith,et al.  Faculty of 1000 evaluation for Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. , 2012 .

[45]  S. M. de la Monte.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. , 2012, Drugs.

[46]  W. Klein,et al.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease , 2011, Neurobiology of Learning and Memory.

[47]  S. Kanba,et al.  Glucose tolerance status and risk of dementia in the community , 2011, Neurology.

[48]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[49]  W. Klein,et al.  Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria , 2010, PloS one.

[50]  W. Klein,et al.  N‐Methyl‐d‐aspartate receptors are required for synaptic targeting of Alzheimer’s toxic amyloid‐β peptide oligomers , 2010, Journal of neurochemistry.

[51]  Ehud Cohen,et al.  Temporal requirements of insulin/IGF-1 signaling for proteotoxicity protection , 2010, Aging cell.

[52]  Ricardo Nitrini,et al.  Post-Mortem diagnosis of dementia by informant interview , 2010, Dementia & neuropsychologia.

[53]  Rosemary O’Connor,et al.  Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.

[54]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[55]  E. Portiansky,et al.  The ependymal route for insulin-like growth factor-1 gene therapy in the brain , 2009, Neuroscience.

[56]  M. Schubert,et al.  The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. , 2009, Current Alzheimer research.

[57]  W. Klein,et al.  Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers , 2009, Proceedings of the National Academy of Sciences.

[58]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[59]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. , 2008, Neurobiology of aging.

[60]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[61]  E. Portiansky,et al.  Restorative effect of insulin-like growth factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction , 2007, Gene Therapy.

[62]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[63]  F. Metzger,et al.  Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis , 2006, Neurobiology of Aging.

[64]  G. Schellenberg,et al.  Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype , 2006, Neurobiology of Aging.

[65]  Ricardo Nitrini,et al.  Brain bank of the Brazilian aging brain study group—a milestone reached and more than 1,600 collected brains , 2006, Cell and Tissue Banking.

[66]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[67]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[68]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[69]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[70]  T. Gómez-Isla,et al.  Serum insulin-like growth factor I regulates brain amyloid-β levels , 2002, Nature Medicine.

[71]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[72]  B. Winblad,et al.  Decreased Plasma Insulin-Like Growth Factor-I Level in Familial Alzheimer’s Disease Patients Carrying the Swedish APP 670/671 Mutation , 1999, Dementia and Geriatric Cognitive Disorders.

[73]  S. Doré,et al.  Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. , 1997, Trends in neurosciences.

[74]  A. Hofman,et al.  Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .

[75]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[76]  M. Viitanen,et al.  Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[77]  P. Gluckman,et al.  Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. , 1991, The Journal of endocrinology.